325 related articles for article (PubMed ID: 30326488)
1. Use and Cost of Actinic Keratosis Destruction in the Medicare Part B Fee-for-Service Population, 2007 to 2015.
Yeung H; Baranowski ML; Swerlick RA; Chen SC; Hemingway J; Hughes DR; Duszak R
JAMA Dermatol; 2018 Nov; 154(11):1281-1285. PubMed ID: 30326488
[TBL] [Abstract][Full Text] [Related]
2. Bundled Payment Models for Actinic Keratosis Management.
Kirby JS; Delikat A; Leslie D; Miller JJ
JAMA Dermatol; 2016 Jul; 152(7):789-97. PubMed ID: 27028662
[TBL] [Abstract][Full Text] [Related]
3. Variation in the Cost of Managing Actinic Keratosis.
Kirby JS; Gregory T; Liu G; Leslie DL; Miller JJ
JAMA Dermatol; 2017 Apr; 153(4):264-269. PubMed ID: 28249074
[TBL] [Abstract][Full Text] [Related]
4. The cost of cancer-related physician services to Medicare.
Maroongroge S; Kim SP; Mougalian S; Johung K; Decker RH; Soulos PR; Long JB; Gross CP; Yu JB
Yale J Biol Med; 2015 Jun; 88(2):107-14. PubMed ID: 26029009
[TBL] [Abstract][Full Text] [Related]
5. Geographic Distribution of Nonphysician Clinicians Who Independently Billed Medicare for Common Dermatologic Services in 2014.
Adamson AS; Suarez EA; McDaniel P; Leiphart PA; Zeitany A; Kirby JS
JAMA Dermatol; 2018 Jan; 154(1):30-36. PubMed ID: 29167867
[TBL] [Abstract][Full Text] [Related]
6. Use of eye care and associated charges among the Medicare population: 1991-1998.
Ellwein LB; Urato CJ
Arch Ophthalmol; 2002 Jun; 120(6):804-11. PubMed ID: 12049587
[TBL] [Abstract][Full Text] [Related]
7. Mortality, Hospitalizations, and Expenditures for the Medicare Population Aged 65 Years or Older, 1999-2013.
Krumholz HM; Nuti SV; Downing NS; Normand SL; Wang Y
JAMA; 2015 Jul; 314(4):355-65. PubMed ID: 26219053
[TBL] [Abstract][Full Text] [Related]
8. Association of Dermatologist Density With the Volume and Costs of Dermatology Procedures Among Medicare Beneficiaries.
Tan SY; Tsoucas D; Mostaghimi A
JAMA Dermatol; 2018 Jan; 154(1):73-76. PubMed ID: 29188286
[TBL] [Abstract][Full Text] [Related]
9. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
Erie JC; Barkmeier AJ; Hodge DO; Mahr MA
Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701
[TBL] [Abstract][Full Text] [Related]
10. Trends in the use and cost of chiropractic spinal manipulation under Medicare Part B.
Whedon JM; Song Y; Davis MA
Spine J; 2013 Nov; 13(11):1449-54. PubMed ID: 23773429
[TBL] [Abstract][Full Text] [Related]
11. Skin Cancers in Medicare Beneficiaries With Actinic Keratoses.
Mohr C; Li Y; Navsaria LJ; Hinkston CL; Shete SS; Margolis DJ; Wehner MR
JAMA Dermatol; 2023 Dec; 159(12):1368-1372. PubMed ID: 37938822
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file.
Brechner RJ; Rosenfeld PJ; Babish JD; Caplan S
Am J Ophthalmol; 2011 May; 151(5):887-895.e1. PubMed ID: 21310390
[TBL] [Abstract][Full Text] [Related]
13. The cost of glaucoma care provided to Medicare beneficiaries from 2002 to 2009.
Quigley HA; Cassard SD; Gower EW; Ramulu PY; Jampel HD; Friedman DS
Ophthalmology; 2013 Nov; 120(11):2249-57. PubMed ID: 23769330
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic considerations in treating actinic keratosis.
Neidecker MV; Davis-Ajami ML; Balkrishnan R; Feldman SR
Pharmacoeconomics; 2009; 27(6):451-64. PubMed ID: 19640009
[TBL] [Abstract][Full Text] [Related]
15. Total cost of care lower among Medicare fee-for-service beneficiaries receiving care from patient-centered medical homes.
van Hasselt M; McCall N; Keyes V; Wensky SG; Smith KW
Health Serv Res; 2015 Feb; 50(1):253-72. PubMed ID: 25077375
[TBL] [Abstract][Full Text] [Related]
16. Health care utilization by old-old long-term care facility residents: how do Medicare fee-for-service and capitation rates compare?
Phillips VL; Paul W; Becker ER; Osterweil D; Ouslander JG
J Am Geriatr Soc; 2000 Oct; 48(10):1330-6. PubMed ID: 11037023
[TBL] [Abstract][Full Text] [Related]
17. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012.
Rogers HW; Weinstock MA; Feldman SR; Coldiron BM
JAMA Dermatol; 2015 Oct; 151(10):1081-6. PubMed ID: 25928283
[TBL] [Abstract][Full Text] [Related]
18. Association of Practice-Level Social and Medical Risk With Performance in the Medicare Physician Value-Based Payment Modifier Program.
Chen LM; Epstein AM; Orav EJ; Filice CE; Samson LW; Joynt Maddox KE
JAMA; 2017 Aug; 318(5):453-461. PubMed ID: 28763549
[TBL] [Abstract][Full Text] [Related]
19. Impact of topical fluorouracil cream on costs of treating keratinocyte carcinoma (nonmelanoma skin cancer) and actinic keratosis.
Yoon J; Phibbs CS; Chow A; Weinstock MA;
J Am Acad Dermatol; 2018 Sep; 79(3):501-507.e2. PubMed ID: 29505863
[TBL] [Abstract][Full Text] [Related]
20. Skin biopsy and skin cancer treatment use in the Medicare population, 1993 to 2016.
Skaggs R; Coldiron B
J Am Acad Dermatol; 2021 Jan; 84(1):53-59. PubMed ID: 32553682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
